Crinetics Pharmaceuticals Valuation
| CRNX Stock | USD 37.35 0.87 2.38% |
At this time, the firm appears to be undervalued. Crinetics Pharmaceuticals shows a prevailing Real Value of $46.56 per share. The current price of the firm is $37.35. Our model approximates the value of Crinetics Pharmaceuticals from analyzing the firm fundamentals such as Return On Equity of -0.4, operating margin of (295.25) %, and Shares Outstanding of 92.74 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Crinetics Pharmaceuticals' valuation include:
Price Book 4.1583 | Enterprise Value | Enterprise Value Ebitda (13.40) | Price Sales 3.3 K | Enterprise Value Revenue 2.6 K |
Undervalued
Today
Please note that Crinetics Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Crinetics Pharmaceuticals is based on 3 months time horizon. Increasing Crinetics Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Crinetics Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Crinetics Stock. However, Crinetics Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 37.35 | Real 46.56 | Target 75.43 | Hype 38.32 |
The intrinsic value of Crinetics Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Crinetics Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Crinetics Pharmaceuticals helps investors to forecast how Crinetics stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Crinetics Pharmaceuticals more accurately as focusing exclusively on Crinetics Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Crinetics Pharmaceuticals' intrinsic value based on its ongoing forecasts of Crinetics Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Crinetics Pharmaceuticals' closest peers.
Crinetics Pharmaceuticals Cash |
|
Crinetics Valuation Trend
Analysing the historical paterns of Crinetics Pharmaceuticals' enterprise value and its market capitalization is a good way to estimate and gauge the value of Crinetics Pharmaceuticals over time and is usually enough for investors to make rational market timing decisions.
Crinetics Pharmaceuticals Total Value Analysis
Crinetics Pharmaceuticals is currently estimated to have valuation of 2.65 B with market capitalization of 3.46 B, debt of 51.73 M, and cash on hands of 408.51 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Crinetics Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.65 B | 3.46 B | 51.73 M | 408.51 M |
Crinetics Pharmaceuticals Investor Information
About 94.0% of the company shares are held by institutions such as insurance companies. The book value of Crinetics Pharmaceuticals was currently reported as 10.3. The company recorded a loss per share of 3.79. Crinetics Pharmaceuticals had not issued any dividends in recent years. Based on the key indicators related to Crinetics Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Crinetics Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February.Crinetics Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Crinetics Pharmaceuticals has an asset utilization ratio of 0.63 percent. This suggests that the Company is making $0.006316 for each dollar of assets. An increasing asset utilization means that Crinetics Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Crinetics Pharmaceuticals Ownership Allocation
Crinetics Pharmaceuticals holds a total of 92.74 Million outstanding shares. The majority of Crinetics Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Crinetics Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Crinetics Pharmaceuticals. Please pay attention to any change in the institutional holdings of Crinetics Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. On October 3, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Crinetics Pharmaceuticals's common stock.Crinetics Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 4.01 M. Net Loss for the year was (214.53 M) with loss before overhead, payroll, taxes, and interest of (49.6 M).About Crinetics Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Crinetics Pharmaceuticals. We calculate exposure to Crinetics Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Crinetics Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 4.6 M | 4.8 M | |
| Pretax Profit Margin | (61.48) | (64.55) | |
| Operating Profit Margin | (63.79) | (66.98) | |
| Net Loss | (61.48) | (64.55) | |
| Gross Profit Margin | 0.81 | 0.85 |
Crinetics Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 58.1 M |
Crinetics Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Crinetics Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Crinetics we look at many different elements of the entity such as Crinetics's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Crinetics Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Crinetics Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Crinetics Pharmaceuticals' worth.Additional Tools for Crinetics Stock Analysis
When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.